Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05104476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Study acronym: AMULET
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 4 versions Re-verified since Oct 28, 2025, no change to tracked fieldsv21-v24
  2. Completion date: May 14, 2026 to Mar 7, 2028 Study sites revised (19)v20 Show 1 more changeShow less
    • Study sites revised (19)

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (19)v19 See this version in full on ClinicalTrials.gov ↗
  4. Results first posted: Dec 27, 2024 Secondary endpoints: details revised at 1 of 18 entriesv18 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 18 entries
  5. Primary endpoint revised Secondary endpoints: 17 to 18 · Study sites revised (19)v17 Show 2 more changesShow less
    • Secondary endpoints: 17 to 18
    • Study sites revised (19)

    See this version in full on ClinicalTrials.gov ↗

Show 15 earlier versionsHide 15 earlier versions
  1. Study sites revised (19)v16 See this version in full on ClinicalTrials.gov ↗
  2. Completion date: Feb 14, 2025 to May 14, 2026 Secondary endpoints: details revised at 1 of 17 entries · Study sites revised (19)v15 Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 17 entries
    • Study sites revised (19)

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date changed from estimate of Nov 20, 2023 to Nov 16, 2023 Completion date: Mar 18, 2024 to Feb 14, 2025v14 Show 1 more changeShow less
    • Completion date: Mar 18, 2024 to Feb 14, 2025
  4. Primary endpoint revised Eligibility criteria expanded, about 78 words · Secondary endpoints revised (17) · Study description expanded, about 33 wordsv13 Show 3 more changesShow less
    • Eligibility criteria expanded, about 78 words
    • Secondary endpoints revised (17)
    • Study description expanded, about 33 words

    See this version in full on ClinicalTrials.gov ↗

  5. Completion date: Mar 1, 2025 to Mar 18, 2024v12
  6. Enrollment target: estimated 60 to confirmed 64 Primary completion date: May 27, 2023 to Nov 20, 2023 · Completion date: Aug 30, 2023 to Mar 1, 2025v11 Show 2 more changesShow less
    • Primary completion date: May 27, 2023 to Nov 20, 2023
    • Completion date: Aug 30, 2023 to Mar 1, 2025
  7. Trial status: Recruiting to Active, Not Recruiting Site details revised at 19 of 19 sitesv10 Show 1 more changeShow less
    • Site details revised at 19 of 19 sites
  8. Study sites: 18 to 19v9
  9. Study sites: 15 to 18v8
  10. Study sites: 5 to 15v7
  11. Study sites: 4 to 5v6
  12. Study sites: 2 to 4v5
  13. Eligibility criteria revised Secondary endpoints revised (17)v4 Show 1 more changeShow less
    • Secondary endpoints revised (17)

    See this version in full on ClinicalTrials.gov ↗

  14. Study sites: 1 to 2v3
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Nov 10, 2021 to Nov 16, 2021v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 10, 2021 to Nov 16, 2021
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
H. Lundbeck A/S
20 trials monitored
See 1 trial at risk
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
Trial Details
NCT Number NCT05104476
Lead Sponsor H. Lundbeck A/S
Conditions Multiple System Atrophy
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov